Hepatitis B Reactivation with Fulminant Hepatitis During Rituximab Chemotherapy in a Patient with Follicular Lymphoma
Kadir Acar 1 * , Mevlüt Hakan Göktepe 1, İlker Polat 1, Hüseyin Atalay 1
More Detail
1 Selcuk University Meram Medical Faculty, Konya, Turkey* Corresponding Author

Abstract

A 52-year-old man was diagnosed Follicular lymphoma with autoimmune hemolytic anemia. At time of diagnosis his HBs Ag was (+), Anti-HBs (-), and HBV DNA was negative. Chemotherapy was interrupted after tree cycles of R-CVP due to elevated liver enzyme. At that time HBV DNA became positive. Lamivudine therapy was started, whereas patient died due to fulminant hepatic failure. The high morbidity and mortality of this complication is one of the major obstacles to completing the standard treatment for lymphoma in HBV carriers. Thus, preventive therapy with nucleoside or nucleotide analogs should be started before the chemotherapy to prevent HBV reactivation.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Case Report

EUR J GEN MED, Volume 7, Issue 1, January 2010, 92-93

https://doi.org/10.29333/ejgm/82823

Publication date: 12 Jan 2010

Article Views: 1279

Article Downloads: 787

Open Access References How to cite this article